Bioequivalence of TTYP01 Tablets in Healthy Adult Subjects
Status:
Completed
Trial end date:
2023-12-14
Target enrollment:
Participant gender:
Summary
This is a Phase 1, Randomized, Open-Label, Three-Treatment, Three-Period Crossover Study to
Assess Bioequivalence and Safety of TTYP01 Tablets to Radicava® Injection, and Radicava ORS®
in Healthy Adult Subjects Under Fasting Conditions.The objective is To characterize the
bioequivalence、safety and tolerability of TTYP01 tablets and Radicava® injection or Radicava
ORS®in healthy adult subjects under fasted conditions.In this study, 30 healthy adult
subjects will receive TTYP01, or Radicava, orRadicava ORS in each period according to the
randomization sequence.